Claude

The People Behind Religare Enterprises

Governance Grade: C+ (Transition) – Religare is in the middle of the most important governance transformation in its history. The Burman family (of Dabur fame) completed a hostile-turned-accepted open offer in early 2025, acquiring ~26% and gaining promoter status after the company operated with 0% promoter holding for years. The old board under Dr. Rashmi Saluja has been replaced, a governance review has been commissioned, and a demerger to separate insurance from financial services is underway. The new regime inherits a legacy of fraud by erstwhile promoters (the Singh brothers), SEBI scrutiny, insider trading allegations against the previous chairperson, and a company still earning subpar returns. Governance is improving directionally, but trust must be earned.

All figures in INR. Data sourced from FY2024 Annual Report, SEBI filings, and public disclosures as of April 2026.

The People Running This Company

The management has been completely reconstituted post-Burman takeover. Dr. Rashmi Saluja, who served as Executive Chairperson from the post-Singh brothers era through 2024, has been replaced. The new board is Burman-aligned with fresh independent directors.

No Results

Key personnel transitions: Dr. Rashmi Saluja was removed after the Burman takeover. SEBI had issued a show-cause notice to her over insider trading allegations. Three proxy advisory firms (SES, IiAS, InGovern) had recommended against her reappointment. The previous CFO Nitin Aggarwal has also departed. Dr. Richa Mishra (Director & Group Head-HR) resigned in April 2026. The leadership bench is thin and still being rebuilt under new ownership.

Burman family context: The Burmans are among India's wealthiest families, primarily known as the promoters of Dabur India Ltd (a leading FMCG company). Their entry into financial services through Religare represents a major strategic bet. They acquired ~26% stake for approximately ~₹2,116 Cr ($255M) through a combination of market purchases via entities like Plutus Wealth Management LLP and a formal open offer.

What They Get Paid

Detailed compensation data from the post-Burman regime is not yet available. The FY2022 annual report (the latest proxy data available) shows the pre-transition compensation structure under Dr. Rashmi Saluja's leadership.

No Results

**Data gap:** Granular compensation figures are not available in the extracted data. The old board granted 68,00,000 stock options under the "Religare Enterprises Limited Employees Stock Option Plan 2019" during Dr. Saluja's tenure. Whether these were disproportionate to company performance (the company was loss-making through most of that period) is a legitimate concern.

No Results

Religare trades at the highest P/E multiple (72.8x) among peers despite the lowest ROE (5.15%) and zero dividend yield. This valuation premium is entirely driven by the Burman takeover narrative and the embedded value of the Care Health Insurance subsidiary, not operational performance. Any compensation that rewarded prior management as if the company were performing well would have been misaligned.

Are They Aligned?

Ownership and Control

Promoter Holding (%)

26.3

Pledge (%)

FII Holding (%)

7.6

DII Holding (%)

9.3

The shareholding chart tells the most important story in Religare's recent history. From FY2023 through Q3 FY2025, the company had zero promoter holding – an extraordinary situation for an Indian financial services company. The Burman family's acquisition created a 25.67% promoter stake overnight in March 2025, which has since crept up to 26.27%. There is zero pledging of promoter shares, which is a positive signal.

FII holding declined from 18.3% to 7.6% over this period, suggesting institutional investors were skeptical of the governance situation. DII holding first rose (to 13.4%) as domestic funds saw value, then pulled back post-takeover.

The Takeover Battle

The Burman acquisition was one of the most contentious corporate battles in recent Indian financial history.

The Burmans began accumulating shares through Plutus Wealth Management LLP from as early as 2022. REL's board under Dr. Saluja actively resisted, arguing the Burmans were "not fit to run a financial services business." The battle involved SEBI, the Securities Appellate Tribunal, and multiple courts.

Proxy advisory firms (SES, IiAS, InGovern) sided against Dr. Saluja's reappointment. SEBI issued a show-cause notice to her over insider trading allegations. The Burman family counter-alleged that Saluja orchestrated complaints against them through shareholders.

A competing offer from Danny Gaekwad Developments & Investments (Bangkok-based) was viewed by market observers as a possible delaying tactic.

Religare's governance history is among the most troubled of any Indian listed company.

**Singh Brothers Fraud (2014-2017):** Erstwhile promoters Malvinder Mohan Singh and Shivinder Mohan Singh diverted funds (estimated ₹740-2,397 Cr) through Religare Finvest to related entities. Both have been charged with criminal conspiracy and cheating. Former CEO Krishnan Subramanian was also arrested (later granted bail). ED and Delhi Police EOW investigations remain active.

SEBI Scrutiny: SEBI examined corporate governance lapses at both Religare and related entity Fortis Healthcare. RBI tagged Religare Finvest as "fraud," though this was contested.

Post-takeover governance review: The new Burman-aligned board has commissioned a full governance review of REL and its subsidiaries (Religare Finvest, Religare Housing Development Finance). The board has also approached the Burman family for funding support.

Demerger – Structural Alignment Play

In February 2026, the boards of REL and Religare Finvest approved a demerger. REL will retain ownership of Care Health Insurance (the crown jewel asset). Financial services operations (lending, broking, investment activities) will be transferred to Religare Finvest on a going-concern basis. RFL will issue shares to REL shareholders on a 1:1 mirror basis. Expected completion is around Q1 FY28.

This demerger is designed to unlock value by separating the high-value insurance business from the lower-margin financial services operations. However, as Livemint noted: "Can a demerger fix what poor governance had broken?" The insurance regulator fined Care Health for claim settlement lapses, suggesting governance culture issues extend beyond the holding company.

Skin-in-the-Game Score

Skin-in-the-Game Score (1-10)

Rationale: Score of 4/10 reflects a company in transition. Positives: Burmans have invested ~₹2,116 Cr of real capital, promoter stake is unpledged, and they are incrementally buying (26.27% and rising). Negatives: The promoter group has no track record in financial services (Dabur is FMCG), the management team is still being assembled, compensation transparency is poor, no dividend has ever been paid under current regime, and the legacy of fraud and regulatory action creates an institutional trust deficit. The score will rise meaningfully if the new management delivers on the governance review, appoints a credible CEO, and the demerger executes cleanly.

Board Quality

No Results

Independence ratio: 7 of 9 (78%) – well above the SEBI-mandated minimum. However, several observations temper this.

The board is heavy on retired bureaucrats (IAS, IPS) and light on financial services operators. For a company running insurance, lending, broking, and housing finance businesses, the lack of deep domain expertise at the board level is a gap.

The chairman (Malay Kumar Sinha) brings security and administrative experience but not financial services governance. This was adequate when REL was a holding company under professional management, but may be insufficient as the Burmans restructure the group.

Only one woman director (Preeti Madan) on a 9-member board is below best-practice standards for an Indian listed company.

The Burman nominees (Arjun Lamba, Suresh Mahalingam) provide the strategic link to the promoter group. Their effectiveness depends on whether the Burmans bring the same operational discipline to financial services that they demonstrated at Dabur.

The Verdict

Governance Grade

C+

Strongest positives:

The single most important governance improvement in Religare's history has occurred: a well-capitalized promoter group (the Burmans) has replaced a zero-promoter structure. Real capital (₹2,100+ Cr) has been deployed, with zero pledging. The contested takeover, while messy, removed a leadership (Dr. Saluja) that proxy advisory firms unanimously opposed. The governance review and demerger plan signal intent to professionalize.

Real concerns:

The Burmans have zero track record in financial services. The management bench below the board is thin and still being assembled. Compensation transparency is poor. The company inherits a legacy of massive fraud (Singh brothers), active ED investigations, SEBI scrutiny, and a Care Health subsidiary that was fined for governance lapses. ROE of 5.15% and P/B of 2.6x means the market is pricing in a turnaround that has not yet materialized in operations.

What would trigger an upgrade to B:

Appointment of a credible, experienced CEO with financial services pedigree. Clean completion of the governance review with transparent disclosure of findings. Execution of the demerger on schedule. Two consecutive years of ROE improvement toward 10%+. Initiation of dividend payments.

What would trigger a downgrade to D:

Evidence that the Burmans are extracting value through related-party transactions (as the Singh brothers did). Regulatory action by RBI or IRDAI against subsidiaries. Departure of key independent directors. Failure to appoint a permanent CEO within 12 months.